Boston Scientific Financial Statements (BSX)
|
|
|
|
Report date
|
|
|
01.08.2025 |
03.11.2025 |
17.02.2026 |
31.03.2026 |
03.08.2026 |
|
31.03.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
5 061 |
5 065 |
5 286 |
5 203 |
5 442 |
|
20 615 |
|
Operating Income, bln rub |
|
|
819.0 |
1 050 |
1 206 |
1 072 |
1 178 |
|
4 147 |
|
EBITDA, bln rub |
? |
|
1 367 |
1 368 |
1 321 |
1 603 |
1 389 |
|
4 763 |
|
Net profit, bln rub |
? |
|
793.0 |
755.0 |
668.0 |
1 337 |
907.0 |
|
3 553 |
|
|
OCF, bln rub |
? |
|
1 286 |
1 343 |
1 364 |
348.0 |
1 474 |
|
4 341 |
|
CAPEX, bln rub |
? |
|
190.0 |
181.0 |
351.0 |
177.0 |
195.0 |
|
899.0 |
|
FCF, bln rub |
? |
|
1 096 |
1 162 |
1 013 |
171.0 |
1 279 |
|
3 442 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
2 605 |
2 492 |
2 731 |
2 541 |
2 670 |
|
10 369 |
|
Cost of production, bln rub |
|
|
1 637 |
1 523 |
1 348 |
1 590 |
1 594 |
|
6 098 |
|
R&D, bln rub |
|
|
526.0 |
514.0 |
569.0 |
516.0 |
554.0 |
|
2 125 |
|
Interest expenses, bln rub |
|
|
90.0 |
87.0 |
90.0 |
90.0 |
96.0 |
|
357.0 |
|
|
Assets, bln rub |
|
|
41 559 |
42 707 |
43 673 |
44 351 |
45 216 |
|
44 351 |
|
Net Assets, bln rub |
? |
|
22 418 |
23 395 |
24 233 |
25 864 |
24 930 |
|
25 864 |
|
Debt, bln rub |
|
|
12 027 |
12 046 |
12 418 |
11 029 |
12 624 |
|
11 029 |
|
Cash, bln rub |
|
|
534.0 |
1 275 |
2 045 |
1 524 |
539.0 |
|
1 524 |
|
Net debt, bln rub |
|
|
11 493 |
10 771 |
10 373 |
9 505 |
12 085 |
|
9 505 |
|
|
Ordinary share price, rub |
|
|
107.4 |
97.6 |
95.4 |
62.8 |
42.7 |
|
45.3 |
|
Number of ordinary shares, mln |
|
|
1 479 |
1 482 |
1 483 |
1 485 |
1 478 |
|
1 485 |
|
|
Market cap, bln rub |
|
|
158 806 |
144 658 |
141 375 |
93 177 |
63 064 |
|
67 259 |
|
EV, bln rub |
? |
|
170 299 |
155 429 |
151 748 |
102 682 |
75 149 |
|
76 764 |
|
Book value, bln rub |
|
|
-2 917 |
-1 980 |
-1 068 |
268 |
-628 |
|
268 |
|
|
EPS, rub |
? |
|
0.54 |
0.51 |
0.45 |
0.90 |
0.61 |
|
2.39 |
|
FCF/share, rub |
|
|
0.74 |
0.78 |
0.68 |
0.12 |
0.87 |
|
2.32 |
|
BV/share, rub |
|
|
-1.97 |
-1.34 |
-0.72 |
0.18 |
-0.43 |
|
0.18 |
|
|
EBITDA margin, % |
? |
|
27.0% |
27.0% |
25.0% |
30.8% |
25.5% |
|
23.1% |
|
Net margin, % |
? |
|
15.7% |
14.9% |
12.6% |
25.7% |
16.7% |
|
17.2% |
|
FCF conversion, % |
|
|
80.2% |
84.9% |
76.7% |
10.7% |
92.1% |
|
72.3% |
|
FCF yield, % |
? |
|
2.08% |
2.61% |
2.56% |
3.69% |
5.75% |
|
5.12% |
|
ROE, % |
? |
|
11.2% |
11.9% |
11.9% |
13.7% |
14.7% |
|
13.7% |
|
ROA, % |
? |
|
6.02% |
6.53% |
6.62% |
8.01% |
8.11% |
|
8.01% |
|
|
P/E |
? |
|
63.5 |
51.9 |
48.9 |
26.2 |
17.2 |
|
18.9 |
|
P/FCF |
|
|
48.0 |
38.3 |
39.0 |
27.1 |
17.4 |
|
19.5 |
|
P/S |
? |
|
8.59 |
7.48 |
7.04 |
4.52 |
3.00 |
|
3.26 |
|
P/BV |
? |
|
-54.4 |
-73.1 |
-132.4 |
347.7 |
-100.4 |
|
251.0 |
|
EV/EBITDA |
? |
|
36.1 |
30.9 |
28.8 |
18.1 |
13.2 |
|
16.1 |
|
Debt/EBITDA |
|
|
2.44 |
2.14 |
1.97 |
1.68 |
2.13 |
|
2.00 |
|
|
R&D/CAPEX, % |
|
|
276.8% |
284.0% |
162.1% |
291.5% |
284.1% |
|
236.4% |
|
|
CAPEX/Revenue, % |
|
|
3.75% |
3.57% |
6.64% |
3.40% |
3.58% |
|
4.36% |
|
| Boston Scientific shareholders |
